BRPI0719228A2 - Composição estabilizada de prostaglandina e - Google Patents

Composição estabilizada de prostaglandina e

Info

Publication number
BRPI0719228A2
BRPI0719228A2 BRPI0719228-2A2A BRPI0719228A BRPI0719228A2 BR PI0719228 A2 BRPI0719228 A2 BR PI0719228A2 BR PI0719228 A BRPI0719228 A BR PI0719228A BR PI0719228 A2 BRPI0719228 A2 BR PI0719228A2
Authority
BR
Brazil
Prior art keywords
prostaglandine
stabilized composition
stabilized
composition
Prior art date
Application number
BRPI0719228-2A2A
Other languages
English (en)
Inventor
Daniel W Frank
Yiping Wang
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of BRPI0719228A2 publication Critical patent/BRPI0719228A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0719228-2A2A 2006-10-11 2007-10-05 Composição estabilizada de prostaglandina e BRPI0719228A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/546,196 US7560489B2 (en) 2006-10-11 2006-10-11 Stabilized prostaglandin E composition
PCT/US2007/021374 WO2008045309A1 (en) 2006-10-11 2007-10-05 Stabilized prostaglandin e composition

Publications (1)

Publication Number Publication Date
BRPI0719228A2 true BRPI0719228A2 (pt) 2015-02-03

Family

ID=39283156

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719228-2A2A BRPI0719228A2 (pt) 2006-10-11 2007-10-05 Composição estabilizada de prostaglandina e

Country Status (12)

Country Link
US (1) US7560489B2 (pt)
EP (1) EP2073634A4 (pt)
JP (1) JP5382800B2 (pt)
KR (1) KR101400359B1 (pt)
AU (1) AU2007307136B2 (pt)
BR (1) BRPI0719228A2 (pt)
CA (1) CA2665611C (pt)
IL (1) IL197885A (pt)
MX (1) MX2009003794A (pt)
NZ (1) NZ576242A (pt)
WO (1) WO2008045309A1 (pt)
ZA (1) ZA200902467B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
EP2343978A4 (en) 2008-10-03 2013-11-27 Nexmed Holdings Inc STABILIZED COMPOSITION FOR TREATING PSORIASIS
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
JP5864543B2 (ja) 2010-05-04 2016-02-17 ネクスメッド ホールディングス，インコーポレイテッド 小分子治療剤の組成物
AU2011249040B2 (en) * 2010-05-04 2014-05-15 Nexmed Holdings, Inc. Therapeutic peptide composition and method
CA2745320A1 (en) 2011-07-06 2013-01-06 Duoject Medical Systems Inc. Reconstitution device
JP5989780B2 (ja) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
US4806354A (en) * 1984-04-06 1989-02-21 Green James P Health food composition
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
GB2372213B (en) * 2000-11-17 2003-07-16 Icebella Enterpises Ltd Applicator and stimulator device
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
ATE366105T1 (de) * 2003-03-03 2007-07-15 Sprl Franpharma Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
AR043476A1 (es) * 2004-09-09 2005-08-03 Dvoskin Victor Oscar Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition

Also Published As

Publication number Publication date
JP5382800B2 (ja) 2014-01-08
WO2008045309A1 (en) 2008-04-17
KR20090064597A (ko) 2009-06-19
NZ576242A (en) 2012-04-27
CA2665611A1 (en) 2008-04-17
ZA200902467B (en) 2010-03-31
AU2007307136B2 (en) 2013-12-05
MX2009003794A (es) 2009-04-24
CA2665611C (en) 2014-11-25
US7560489B2 (en) 2009-07-14
JP2010506831A (ja) 2010-03-04
EP2073634A1 (en) 2009-07-01
US20080090911A1 (en) 2008-04-17
AU2007307136A1 (en) 2008-04-17
KR101400359B1 (ko) 2014-06-19
IL197885A (en) 2016-04-21
IL197885A0 (en) 2009-12-24
EP2073634A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
EP2083864A4 (en) ANTAGONISTS OF PCSK9
EP2083859A4 (en) PCSK9 ANTAGONISTS
EP2083860A4 (en) PCSK9 ANTAGONISTS
BRPI0906980A2 (pt) Composição de derivados e maleatados
ATE528296T1 (de) Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on
EP2083049A4 (en) HARDENABLE POLYORGANOSILOXANE COMPOSITION
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
EP2013701A4 (en) DISAMBING OF NAMED CHARACTERS
EP2046290A4 (en) AQUEOUS DRONABINOL FORMULATIONS
EP2079544A4 (en) ARSENIC ABSORBENT COMPOSITION AND METHODS OF USE
BRPI0716325A2 (pt) Composição antimicrobianas
BRPI0810179A2 (pt) Composições de oligo-guluronato e galacturonato
BRPI0715712A2 (pt) Composição farmacêutica
DK3136030T3 (da) Fremgangsmåde til lyofilisering
NO20084339L (no) Stabiliserte polypeptidsammensetninger
CR10562A (es) Nuevos derivados de piridazina
BRPI0719393A2 (pt) Composição farmacêutica
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
EP2043136A4 (en) FILMING COMPOSITION
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
FR2899479B1 (fr) Composition cicatrisante
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FERRING INTERNATIONAL CENTER S.A. (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 37/08 , A01N 53/00 , A61K 31/19

Ipc: A61K 31/5575 (2000.01), A61K 31/557 (1980.01), A61

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements